Core Viewpoint - A class action securities lawsuit has been filed against KBR, Inc. alleging securities fraud that affected investors between May 6, 2025, and June 19, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that KBR, Inc. made false statements regarding its partnership with HomeSafe, despite knowing that the U.S. Department of Defense had concerns about HomeSafe's ability to fulfill a global household goods contract [2]. - It is alleged that the defendants misled investors about KBR's business operations and prospects, which were materially false and lacked a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until November 18, 2025, to request to be appointed as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant recoveries for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Zynex, Inc. is implementing strategic initiatives to ensure long-term success, including engaging a financial advisory firm and forming a Special Committee to explore various strategic alternatives [1][2][5]. Strategic Initiatives - Zynex has engaged Province, LLC to evaluate strategic alternatives, including capital raising and restructuring strategies [2]. - A Special Committee has been formed by the Board, consisting of independent directors, to oversee the assessment of these strategic alternatives [4]. Leadership Changes - Paul Aronzon has been appointed to the Board of Directors, bringing over 40 years of experience in corporate restructuring and advisory roles [3]. - Aronzon will serve as Chair of the Special Committee, which will work closely with management and Province to assess strategic options [4]. Management Statements - CEO Steven Dyson emphasized the company's commitment to exploring all avenues for a new future for Zynex through these strategic steps [5].

Core Insights - Lifeward Ltd. reported a record quarter for Medicare beneficiary placements, indicating strong commercial execution and operational improvements [3][9] - The company achieved a 16% year-over-year decrease in quarterly cash burn and a 27% decrease in quarterly Non-GAAP operating loss, reflecting ongoing efficiency initiatives [4][6] - Lifeward secured a $3.0 million loan agreement with Oramed Ltd. to support its operations and strategic initiatives [9][10] Financial Performance - Revenue for Q3 2025 was $6.2 million, a slight increase of approximately 1% from $6.1 million in Q3 2024, and an 8% increase from $5.7 million in Q2 2025 [4] - Revenue from traditional products, including ReWalk Personal exoskeletons, rose to $3.1 million, up 24% year-over-year, driven by Medicare-related sales [4] - Gross margin improved to 43.7% in Q3 2025, compared to 36.2% in Q3 2024, primarily due to lower production costs following the closure of the Fremont manufacturing facility [4][5] Operating Expenses and Losses - Total operating expenses in Q3 2025 were $5.9 million, up from $5.4 million in Q3 2024, but adjusted operating expenses decreased to $5.7 million from $6.7 million year-over-year [5] - The operating loss for Q3 2025 was $3.1 million, slightly improved from a loss of $3.2 million in Q3 2024, with adjusted operating loss decreasing to $3.0 million from $4.1 million [6] - Net loss for Q3 2025 was $3.2 million, or $0.20 per share, compared to a net loss of $3.1 million, or $0.35 per share, in Q3 2024 [7] Liquidity and Guidance - As of September 30, 2025, Lifeward had $2.0 million in unrestricted cash and cash equivalents, with cash used in operations improving to $3.8 million from $4.5 million in Q3 2024 [8] - The company reaffirmed its full-year 2025 guidance, expecting revenue in the range of $24 to $26 million and a projected non-GAAP net loss between $12 to $14 million [11]

Teleflex Incorporated Vascular Intervention Investor Call November 14, 2025 Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) An audio replay of the call will be available beginning at 11:00 am Eastern Time on November 14, 2025 either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S.) or 1 609 800 9909 (all other locations). The confirmation code is 61210. Today's Speake ...

Group 1 - Naspers Limited (NPSNY) has seen a 20.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Suzano S.A. (SUZ) has experienced a 7.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - EverCommerce Inc. (EVCM) has reported a significant 42.9% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] Group 2 - LeMaitre Vascular, Inc. (LMAT) has seen a 9.6% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Teradyne, Inc. (TER) has experienced a 10.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3]

Core Insights - Picard Medical, Inc. successfully completed its initial public offering (IPO) on September 2, 2025, raising approximately $19.5 million in gross proceeds, which will be used to strengthen its balance sheet and accelerate research and development [4][7]. Financial Performance - Third quarter revenue reached $1.19 million, a 35% increase from the same period in 2024, driven by higher U.S. product sales and increased driver rentals [5]. - The cost of revenue declined by 15% year-over-year, resulting in a gross loss reduction of 81% to $0.13 million [5]. - Operating expenses decreased by 11% to $3.36 million, leading to a narrowed operating loss of $3.36 million compared to $3.77 million in Q3 2024 [6]. - For the nine-month period ending September 30, 2025, revenue totaled $3.93 million, an 11% increase from 2024, while the operating loss remained consistent at $10.3 million [7]. Strategic Developments - The company secured additional patent protection for its SynCardia Total Artificial Heart (STAH), reinforcing its commitment to life-saving technology [3]. - Two independent directors, Sam Van and George Ye, were appointed to the board to provide leadership and guidance as the company transitions to a public entity [3][7]. - A new patent (U.S. Patent No. 12,383,722 B2) was granted for the next-generation fully implantable SynCardia Total Artificial Heart, expanding the company's intellectual property portfolio [7]. Market Position - Picard Medical, through its subsidiary SynCardia, is the only company with commercially available total artificial heart technology for patients with end-stage heart failure, with over 2,100 implants performed globally [10].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [2][4]. Group 1: Lawsuit Details - The lawsuit has been filed against Inspire Medical Systems and certain senior executives, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [4]. - Investors have until January 5, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of Minnesota [4]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [5]. Group 3: Stock Performance and Issues - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an "elongated timeframe," leading to a reduction in 2025 earnings per share guidance by over 80% [8]. - The stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025, following this announcement [9]. Group 4: Allegations of Mismanagement - The lawsuit alleges that Inspire failed to adequately prepare clinicians and payors for the rollout of Inspire V, resulting in significant delays and weak demand due to excess inventory of older devices [7][8].

Core Insights - Encision Inc. reported financial results for the second quarter of fiscal 2026, ending September 30, 2025, highlighting a total net revenue of $1.52 million [1] - The company experienced a quarterly net loss of $268 thousand, translating to a loss of $(0.02) per diluted share [1] Financial Performance - The quarterly product net revenue was $1.48 million, while service net revenue was $46 thousand, contributing to the total net revenue of $1.52 million [1] - The net loss for the quarter was $268 thousand, indicating challenges in achieving profitability [1]

Core Insights - Heidelberg Engineering joins the Collaborative Community on Ophthalmic Innovation (CCOI) under EssilorLuxottica's Vision Architect membership, indicating a commitment to patient-centric innovation through collaboration and scientific rigor [1][2][3] Company Overview - Heidelberg Engineering specializes in high-quality multimodal ophthalmic imaging, supporting the diagnosis and treatment of various retinal diseases, including glaucoma and age-related macular degeneration (AMD) [5] - The company’s SPECTRALIS platform offers superior retinal image quality, while the ANTERION platform provides an all-in-one anterior segment solution based on high-quality OCT technology [5] Industry Collaboration - CCOI serves as a public-private forum that brings together various stakeholders, including patients, clinicians, and industry players, to expedite the development and adoption of ophthalmic medical products [2][8] - Heidelberg Engineering will engage in CCOI's AMD and glaucoma workstreams, focusing on clinically meaningful endpoints and interoperable data standards to facilitate the integration of innovative diagnostics and therapies [2][3] Strategic Contributions - The company will support CCOI in defining patient-centered measures and improving data quality and interoperability, leveraging its expertise in multimodal imaging [7] - Engagement in discussions on the ethical deployment of AI and digital tools will ensure that AI workflows enhance access and outcomes in eye care [7] Educational Initiatives - Heidelberg Engineering aims to promote evidence-based best practices and raise awareness of advancements in vision science across various communities, including clinical and regulatory [7]

Core Insights - Milestone Scientific Inc. reported a significant increase in share price, surging 35.67% in after-hours trading to $0.52 following the release of its third-quarter results, which showed lower costs and improved losses [1] Financial Performance - The company reduced its operating expenses by over $500,000 in Q3 compared to the same period last year, contributing to improved margins [2] - Operating loss decreased by 23% to approximately $1.1 million from $1.5 million a year earlier, while net loss narrowed to $1.2 million, or $0.01 per share, compared to $1.5 million, or $0.02 per share, in Q3 2024 [3] - Third-quarter revenue was about $2.4 million, slightly down from $2.5 million in the same quarter last year, with lower domestic dental sales offset by stronger international demand and steady recurring medical revenue [4] - For the first nine months of the year, revenue increased by 5% to $6.9 million from $6.6 million, driven by growth in international dental markets and higher recurring revenue in the medical segment [4] Strategic Developments - The CEO highlighted the company's positive outlook on growing utilization and recurring revenue from CompuFlo disposables, alongside advancements in its reimbursement strategy, which includes recent Medicare payment-rate assignments and expanded commercial coverage [5] Stock Performance - Year-to-date, Milestone Scientific's shares have declined by 59.61%, with stock prices fluctuating between $0.35 and $1.39 over the past year, and a market capitalization of approximately $29.8 million [6]